¿TU PERRO ESTÁ TRATANDO
DE DECIRTE ALGO?

1. Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015;26(3):171-179, e35.

2. Sousa CA. Glucocorticoids in veterinary dermatology. In: Bonagura JD, Twedt DC, eds. Kirk’s Current Veterinary Therapy. 14th ed. St. Louis, MO: Saunders Elsevier; 2009:400-404.

3. Gonzalez A, Bowman J, Fici G, Zhang M, Mann D, Mitton-Fry M. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. In press.

4. Cosgrove SB, Wren JA, Cleaver DM, et al. A Blinded, Randomized, Placebo-controlled Trial of the E cacy and Safety of the Janus Kinase Inhibitor Oclacitinib (Apoquel®) in Client-owned Dogs with Atopic Dermatitis. Vet Dermatol

5. Gadeyne C, Little P, King VL, Edwards N, Davis K, Stegemann MR. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014;25(6):512-518, e86. doi: 10.1111/vde.12166.

6. Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5): 479-e114. doi: 10.1111/vde.12047

© 2022 Zoetis. Todos los derechos reservados. Registros propiedad de Zoetis México, S. de R.L. de C.V. Apoquel 5.4 mg (oclacitinib) Reg. Q-1196-717, Apoquel 16 mg (oclacitinib) Reg. Q-1196-718, Apoquel 3.6 mg (oclacitinib) Reg. Q-1196-719. Paseo de los Tamarindos Número 60 Planta Baja, Colonia Bosques de las Lomas, Alcaldía de Cuajimalpa de Morelos, México, Ciudad de México, Código Postal 05120. USO VETERINARIO. CONSULTE AL MÉDICO VETERINARIO. SU VENTA REQUIERE RECETA MÉDICA.